Immune Checkpoint Inhibitor Toxicities

Julian A. Marin-Acevedo, Razvan M. Chirila, Roxana S Dronca

Research output: Contribution to journalReview article

Abstract

Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase.

Original languageEnglish (US)
Pages (from-to)1321-1329
Number of pages9
JournalMayo Clinic proceedings
Volume94
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Neoplasms
Therapeutics
Immunosuppressive Agents
Immunotherapy
Melanoma
Adrenal Cortex Hormones
Colon
Kidney
Lung
Skin
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immune Checkpoint Inhibitor Toxicities. / Marin-Acevedo, Julian A.; Chirila, Razvan M.; Dronca, Roxana S.

In: Mayo Clinic proceedings, Vol. 94, No. 7, 01.07.2019, p. 1321-1329.

Research output: Contribution to journalReview article

Marin-Acevedo, Julian A. ; Chirila, Razvan M. ; Dronca, Roxana S. / Immune Checkpoint Inhibitor Toxicities. In: Mayo Clinic proceedings. 2019 ; Vol. 94, No. 7. pp. 1321-1329.
@article{fb6eca5a6c694e809f2b046eeb099f63,
title = "Immune Checkpoint Inhibitor Toxicities",
abstract = "Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase.",
author = "Marin-Acevedo, {Julian A.} and Chirila, {Razvan M.} and Dronca, {Roxana S}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.mayocp.2019.03.012",
language = "English (US)",
volume = "94",
pages = "1321--1329",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitor Toxicities

AU - Marin-Acevedo, Julian A.

AU - Chirila, Razvan M.

AU - Dronca, Roxana S

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase.

AB - Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase.

UR - http://www.scopus.com/inward/record.url?scp=85067586771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067586771&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2019.03.012

DO - 10.1016/j.mayocp.2019.03.012

M3 - Review article

VL - 94

SP - 1321

EP - 1329

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -